The Chiesi Total Care Program Assists With:

Payer coverage and access

Verify patient's benefit coverage and financial assistance eligibility (including Commercial insurance, Government Insurance, and No insurance)

Prior authorization and support

Call 1-833-670-6464 to:

  • Determine documentation needed by the patient's health plan
  • Navigate payer appeals and exceptions

Financial assistance

Options are tailored to the individualized needs of your patients

A dedicated Total Care team that includes:

  • Patient service coordinators who assist those prescribed FILSUVEZ
  • Nursing support
  • Worry-free refills including 24-hour pharmacist availability and medication delivered right to your patient's door

Resource center

Our resources include helpful links that provide more detailed information on Epidermolysis Bullosa and FILSUVEZ

Access and Support Services

Download a FILSUVEZ Starter Kit today

Helpful Links for Your Patients

FILSUVEZ® (birch triterpenes) topical gel

Indication and Important Safety Information

INDICATION

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

IMPORTANT SAFETY INFORMATION

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

Indication and Important Safety Information

INDICATION

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

IMPORTANT SAFETY INFORMATION

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.